 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12345678910» |
- | aztreonam/avibactam (PF-06947387) / Pfizer, AbbVie, relebactam (MK-7655) / Merck (MSD)
Preclinical, Journal, Gram negative: In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-?-Lactamase-Producing Gram-Negative Bacteria. (Pubmed Central) - Oct 27, 2023
As previously demonstrated for an aztreonam/ceftazidime-avibactam combination, aztreonam plus imipenem-relebactam and aztreonam plus meropenem-vaborbactam might be useful options, but with potentially lower efficiency, to treat infections caused by aztreonam-non-susceptible MBL-producing Gram-negative strains.
- | Journal: Management strategies for severe Pseudomonas aeruginosa infections. (Pubmed Central) - Oct 12, 2023
Combination therapy does not reduce mortality, but may be necessary for empirical treatment. Short-term treatment of severe P. aeruginosa infections should be preferred when it is expected that the clinical situation resolves rapidly.
- | Fetroja (cefiderocol) / Shionogi
Preclinical, Journal: In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel ?-lactam/?-lactamase inhibitors. (Pubmed Central) - Oct 5, 2023
Cross-resistance between cefiderocol and ceftolozane/tazobactam was evident, but not with ceftazidime/avibactam or imipenem/relebactam. Reduced cefiderocol susceptibility was mediated by mutations in ampC and tonB-dependent receptors.
- | imipenem/relebactam / Merck (MSD)
Journal, Gram negative: Susceptibility of gram-negative isolates collected in Taiwan to imipenem/relebactam and comparator agents - SMART 2018-2021. (Pubmed Central) - Sep 21, 2023
Reduced cefiderocol susceptibility was mediated by mutations in ampC and tonB-dependent receptors. Based on our in
- Impact of a Recent Change in Tobramycin Breakpoints (CLSI) on the Proportion of Pseudomonas aeruginosa Clinical Isolates that are Multidrug-Resistant: CANWARD, 2016 to 2021 (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_3295;
- Difficult to treat GES and KPC harboring Pseudomonas aeruginosa: Evaluation of in vivo efficacy of (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_3282;
- imipenem/relebactam / Merck (MSD)
Determining the activity of imipenem/relebactam (I/R) plus aztreonam (ATM) against constitutive Pseudomonas derived cephalosporinase (PDC)- and metallo-?-lactamase (MBL)-producing Pseudomonas aeruginosa in a hollow fiber infection model (HFIM) (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_3276;
- Fetroja (cefiderocol) / Shionogi
Antimicrobial Activity of Cefiderocol and Comparator Agents Against Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia by Infection Type from United States Hospitals in the SENTRY Antimicrobial Surveillance Program (2020-2022) (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_3275;
- Fetroja (cefiderocol) / Shionogi
Activity of Cefiderocol and Comparator Agents Against Pediatric Isolates of Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia from the SENTRY Surveillance Program (2020-2022) (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_3274;
- Rates of Susceptibility and Heteroresistance to Novel Antibiotic Combinations in Carbapenem-Resistant Enterobacterales Isolates - Emory Healthcare, 2016-2021 (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_3268;
- Fetroja (cefiderocol) / Shionogi
Activity of Cefiderocol and Comparator Agents Against Achromobacter and Burkholderia Isolates, Collected During 2020-2022 as Part of SENTRY Antimicrobial Surveillance Program (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_3245;
- aztreonam/avibactam (PF-06947387) / Pfizer, AbbVie
Activity of Aztreonam-avibactam and Carbapenem-resistant Enterobacterales (CRE) Isolates Collected in a Six-year Period (2017 (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_3239;
- imipenem/relebactam / Merck (MSD)
A Phase II Prospective Randomized Study to Assess Imipenem-Relebactam in the Management of Cancer Patients with Febrile Neutropenia (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2564;
- imipenem/relebactam / Merck (MSD)
Low prevalence of OXA-48-like carbapenemases and susceptibility to imipenem/relebactam among carbapenem-resistant non-Morganellaceae Enterobacterales isolates from Latin America (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2334;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Cross-resistance of Ceftolozane-Tazobactam and Imipenem-Relebactam Against Clinical P. aeruginosa Isolates from Bloodstream and Respiratory Tract Infections (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2333;
- imipenem/relebactam / Merck (MSD)
Activity of Imipenem/Relebactam Against Carbapenem-Resistant Non-Morganellaceae Enterobacterales (NME) in the United States (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2331;
- Activity of Novel ?-Lactam/?-Lactamase Inhibitor Combinations against Serine-Carbapenemase producing Carbapenem-Resistant Pseudomonas aeruginosa (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2304;
- Fetroja (cefiderocol) / Shionogi
In vitro Activity of Cefiderocol and Comparator Agents Against Enterobacterales From United States Hospitals Stratified by Infection Type (2020-2022) (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2291;
- Evaluation of the EDTA-modified Carbapenem Inactivation Method (eCIM) with Using the EDTA Blood Collection Tube for Differentiating the Serine- and Metallo-?-lactamase (MBL) Producing Enterobacterales. (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_1898;
- Carbapenem-resistant Enterobacterales reported to the National Healthcare Safety Network Multidrug-Resistant Organism & Clostridioides difficile Infection Module, January 2018 to July 2022 (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_1710;
- aztreonam/avibactam (PF-06947387) / Pfizer, AbbVie
Evaluation of Aztreonam-Avibactam In Vitro Activity Against VIM and GES ?-lactamase Producing, Carbapenem-Resistant Pseudomonas aeruginosa Collected from Contaminated Artificial Tear Products (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_1294;
- Fetroja (cefiderocol) / Shionogi
Cefiderocol Activity Against Multidrug-resistant and Molecularly Characterized Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus complex Clinical Isolates Causing Infection in United States Hospitals (2020 (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_1240;
- Fetroja (cefiderocol) / Shionogi
Activity of Cefiderocol and Comparator Agents Against Molecularly Characterized Multidrug-resistant Enterobacterales Clinical Isolates from United States Hospitals (2020 (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_1238;
- imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Emergence of INDEL Mutations in KPC-2: Insights into Ceftazidime-Avibactam and Imipenem-Relebactam Efficacy (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_1228;
- | Journal: Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era-Challenges and Solutions. (Pubmed Central) - Aug 26, 2023
KPC-producing isolates were also highly susceptible to colistin (92%)...ST-307 prevailed in KPC and ST-11 in NDM isolates. Despite the excellent activity of new antimicrobials, rational antibiotic policy must be thoroughly followed, supported by complementary treatments and strict anti-epidemic precautions.
- | Journal: Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase. (Pubmed Central) - Aug 21, 2023
Of note, KPC producers resistant to ceftazidime/avibactam and harbouring mutated bla exhibited higher MICs of cefiderocol (median MIC 16?mg/L, IQR 16-16) than strains harbouring WT bla (cefiderocol 9?mg/L, IQR 1.5-16). Our results highlight the need for continuous monitoring of CPE to limit widespread MDR pathogens carrying multiple mechanisms conferring resistance to novel antimicrobial molecules.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Journal: Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in central and northern Europe (Belgium, Norway, Sweden, Switzerland)-SMART 2017-21. (Pubmed Central) - Aug 14, 2023
Carbapenemase gene carriage among Enterobacterales and P. aeruginosa isolates was generally low (<1%) or completely absent with one exception: an estimated 2.7% of P. aeruginosa isolates from Belgium carried an MBL. Recent clinical isolates of Enterobacterales and P. aeruginosa collected in four central and northern European countries were highly susceptible (?95%) to ceftolozane/tazobactam and imipenem/relebactam.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland. (Pubmed Central) - Aug 11, 2023
Overall, 77% of the strains were susceptible to meropenem-vaborbactam, 63% was susceptible to ceftazidime-avibactam, and 62% susceptible to imipenem-relebactam. Those data may contribute to optimize the choice of first line therapy for treating infections due to CPE.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal, Gram negative: The epidemiology and microbiological characteristics of infections caused by Gram-negative bacteria in Qatar: national surveillance from the Study for Monitoring of Antimicrobial Resistance Trends (SMART): 2017 to 2019. (Pubmed Central) - Aug 7, 2023
Genomic characteristics of 70 Enterobacterales including 48 carbapenem-resistant, revealed prevalence of ?-lactamases from all classes, predominated by bla while carbapenem resistance revealed paucity of bla and dominance of bla and bla resistance genes. Surveillance of GNB from Qatar showed prevalence of key pathogens similar to other regions but demonstrated significant resistance patterns to existing and novel antimicrobials with different underlying resistance mechanisms.
- | imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: In vitro activity of imipenem/relebactam and ceftazidime/avibactam against carbapenem-resistant Klebsiella pneumoniae from blood cultures in a University hospital in Serbia. (Pubmed Central) - Aug 3, 2023
Surveillance of GNB from Qatar showed prevalence of key pathogens similar to other regions but demonstrated significant resistance patterns to existing and novel antimicrobials with different underlying resistance mechanisms. Minimum inhibitory concentration (MIC) values of the examined antimicrobial drugs was determined by
- | Journal: Genomics and Antimicrobial Susceptibility of Clinical Pseudomonas aeruginosa Isolates from Hospitals in Brazil. (Pubmed Central) - Jul 29, 2023
The most active drug was cefiderocol (100%), followed by ceftazidime-avibactam (94.1%), ceftolozane-tazobactam (92.4%), and imipenem-relebactam (81.5%)...Several virulence genes (exoSTUY, toxA, aprA, lasA/B, plcH) were also identified. We found that new antimicrobials are effective against the diverse P. aeruginosa population that has been circulating in Brazilian hospitals in recent years.
- || Review, Journal, Gram negative: Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review. (Pubmed Central) - Jul 29, 2023
Nonetheless, several novel agents lack pediatric indications approved by the Food and Drug Administration (FDA) and the European Medicine Agency (EMA), leading to uncertain pediatric-specific treatment strategies and uncertain dosing regimens in the pediatric population. In this narrative review we have summarized the available clinical and pharmacological data, current limitations and future prospects of novel beta lactam antibiotics in the pediatric population.
- | Fetroja (cefiderocol) / Shionogi
Preclinical, Journal: In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates. (Pubmed Central) - Jul 29, 2023
4 mg/L represented A. baumannii international clone (IC) 1 and harbored a metallo-?-lactamase. While cefiderocol is a useful addition to the limited armamentarium of drugs targeting this problematic pathogen, a considerable part of CRAB isolates had elevated MIC values in a range of 4 --> 32 mg/L, including all isolates with a metallo-?-lactamase.
- || Fetroja (cefiderocol) / Shionogi
Review, Journal: Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients. (Pubmed Central) - Jul 18, 2023
New BL/BLI combinations and cefiderocol represent long-awaited options for improving the management of DTR-GNB infections. Several research axes must be explored to better define the positioning and appropriate administration scheme of these drugs in critically ill patients.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Journal: Susceptibility profile and ?-lactamase content of global Pseudomonas aeruginosa isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam-SMART 2016-21. (Pubmed Central) - Jun 30, 2023
P. aeruginosa with ceftolozane/tazobactam-resistant/imipenem/relebactam-susceptible and imipenem/relebactam-resistant/ceftolozane/tazobactam-susceptible phenotypes were uncommon and harboured diverse resistance determinants.
- | Recarbrio (relebactam/imepenem/cilastatin) / Merck (MSD)
Journal: Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis. (Pubmed Central) - Jun 29, 2023
P3
These results lend further support to the noninferiority of IMI/REL to piperacillin/tazobactam and suggests that pathogen eradication may be more likely with IMI/REL. NCT02493764.
- || Review, Journal: New Antimicrobials for the Treatment of Neonatal Sepsis Caused by Multi-Drug-Resistant Bacteria: A Systematic Review. (Pubmed Central) - Jun 28, 2023
novel antibiotics may be considered in newborns for the treatment of MDR Gram negatives with limited treatment options and for Gram positives with resistance concerns. Further studies are needed to address their effectiveness and safety in newborns.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Invanz (ertapenem) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Journal, Gram negative: Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020. (Pubmed Central) - Jun 20, 2023
Carbapenemases were rare among both P. aeruginosa (one isolate) and Enterobacterales (three isolates). Most Enterobacterales isolates tested from ICU and non-ICU patients in Hong Kong hospitals in 2017-2020 were susceptible to meropenem and ertapenem (?98%); imipenem was less active (89% susceptible).
- | imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa. (Pubmed Central) - Jun 19, 2023
CZA also showed good activity against CAZ-NS and IPM-NS P. aeruginosa, primarily by inhibiting KPC-2 enzyme and overproduced AmpC, supporting the clinical use of CZA in the treatment of infections caused by DTR-P. aeruginosa.
- | Journal: Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant Enterobacterales Isolates. (Pubmed Central) - Jun 19, 2023
Plazomicin and ceftazidime-avibactam exhibited the lowest nonsusceptibility rates and may be considered promising agents in the management of carbapenem-resistant Enterobacterales infections. We note also that antibiotic activity is influenced by genotypes and that understanding the geographic region's molecular epidemiology could aid in the definition of the presumptive utility of novel agents and contribute to antibiotic decision-making.
- | imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: The Effectiveness of Imipenem-Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 ?-Lactamase. (Pubmed Central) - May 27, 2023
We note also that antibiotic activity is influenced by genotypes and that understanding the geographic region's molecular epidemiology could aid in the definition of the presumptive utility of novel agents and contribute to antibiotic decision-making. Imipenem-relebactam overcame the resistance of the D179 variants, suggesting that this combination will be active against clinical isolates harboring these derivatives of KPC-2.
- | imipenem/relebactam / Merck (MSD), Fetroja (cefiderocol) / Shionogi, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal, Combination therapy, Gram negative: Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria. (Pubmed Central) - May 27, 2023
Moreover, the combination of CAZ-AVI/SULB showed synergistic activity in CAZ-AVI-resistant CRE strain. In conclusion, although further analyses are needed to confirm these results, our work showed the efficacy of CFD when used for synergistic formulations.
- | Fetroja (cefiderocol) / Shionogi
Journal: Citrobacter freundii resistant to novel ?-lactamase inhibitor combinations and cefiderocol, co-producing class A, B and D carbapenemases encoded by transferable plasmids. (Pubmed Central) - May 19, 2023
In conclusion, although further analyses are needed to confirm these results, our work showed the efficacy of CFD when used for synergistic formulations. The finding of enterobacterial strains carrying multiple carbapenemase genes on transferable plasmids is alarming, because similar strains could provide an important reservoir for disseminating these clinically relevant resistance determinants.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022). (Pubmed Central) - May 15, 2023
All 3 BLIs were very active against KPC producers and none were active against MBL producers. Ceftazidime-avibactam exhibited greater activity against OXA-48-type producers than meropenem-vaborbactam and imipenem-vaborbactam.
- || Review, Journal: What to Do with the New Antibiotics? (Pubmed Central) - Apr 28, 2023
Knowledge of the risk factors for multidrug-resistant Gram-negative bacilli (local ecology, prior colonization, failure of prior antibiotic therapy, and source of infection) seems necessary in order to optimize antibiotic prescriptions. In this review, we will assess these different antibiotics according to the epidemiological data.
- | aztreonam/avibactam (PF-06947387) / Pfizer, AbbVie, imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Chimeric Tobramycin-Based Adjuvant TOB-TOB-CIP Potentiates Fluoroquinolone and ?-Lactam Antibiotics against Multidrug-Resistant Pseudomonas aeruginosa. (Pubmed Central) - Apr 17, 2023
Moreover, the susceptibility breakpoints of ceftazidime, aztreonam, and imipenem were reached using the triple combination of chimera 4 with ceftazidime/avibactam, aztreonam/avibactam, and imipenem/relebactam, respectively, against ?-lactamase-harboring P. aeruginosa. Our findings demonstrate that tobramycin-based chimeras form a novel class of antibiotic potentiators capable of restoring the activity of antibiotics against P. aeruginosa.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Susceptibility of Multidrug-Resistant Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from Germany to Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Imipenem-Relebactam. (Pubmed Central) - Apr 11, 2023
Thirty-three (11.2%) P. aeruginosa isolates were resistant to both carbapenems and 30 (10.2%) P. aeruginosa showed resistance to ?3 antimicrobials/antimicrobial groups (among piperacillin-tazobactam, ceftazidime, tobramycin, carbapenems, and fluoroquinolones)...Only two K. pneumoniae and four P. aeruginosa isolates were resistant to all three beta-lactam/beta-lactamase-inhibitor combinations. However, this favorable result should be viewed in light of the relatively low prevalence of MDR organisms that require these agents in Germany.
- | Journal, Gram negative: Treatment options for multidrug-resistant Gram-negatives in urinary tract infections. (Pubmed Central) - Apr 4, 2023
However, this favorable result should be viewed in light of the relatively low prevalence of MDR organisms that require these agents in Germany. To ensure prudent use and to avoid the development of resistance to novel anti-infective substances, an interdisciplinary approach, including urologists, microbiologists, and infectious disease physicians, is strongly advised.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Deciphering variable resistance to novel carbapenem-based ?-lactamase-inhibitor combinations in a multiclonal outbreak by KPC carbapenemase-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam. (Pubmed Central) - Apr 4, 2023
In this multi-clonal outbreak of KPC-Kp, the overproduction of KPC-3 was the leading mechanism of cross-resistance to CZA and MVB, whereas resistance to IMR appeared less affected. The emergence and dissemination of similar resistance mechanisms may have relevant clinical and diagnostic implications, and their surveillance is warranted.
- imipenem/relebactam / Merck (MSD)
Salvage therapy with imipenem-relebactam in carbapenem-resistant Pseudomonas aeruginosa infections (C / 05) - Apr 2, 2023 - Abstract #ECCMID2023ECCMID_5805;